OBJECTIVE: Although HAART can suppress genital shedding and sexual transmission of HIV, men who have sex with men (MSM) have experienced a resurgent HIV epidemic in the HAART era. Many HIV-infected MSM continue to engage in unsafe sex, and sexually transmitted infections (STIs) or other factors may promote genital HIV shedding and transmission in this population despite HAART. In this study, we determined the prevalence of seminal HIV shedding in HIV-infected MSM on stable HAART, and its relationship with a number of clinical, behavioral and biological variables. DESIGN: Sexually active HIV-infected men using HAART were recruited from an MSM health clinic to provide semen and blood samples. METHODS: HIV levels were assessed in paired semen and blood samples by PCR. Clinical and behavioral data were obtained from medical records and questionnaires. Herpes simplex virus 2 (HSV-2) serostatus, seminal HSV-2 DNA, and markers of genital inflammation were measured using standard laboratory methods. RESULTS: Overall, HIV-1 was detected in 18 of 101 (18%) blood and 30 of 101 (30%) semen samples. Of 83 men with undetectable HIV in blood plasma, 25% had HIV in semen with copy numbers ranging from 80 to 2560. Multivariate analysis identified STI/urethritis (P = 0.003), tumor necrosis factor α (P = 0.0003), and unprotected insertive anal sex with an HIV-infected partner (P = 0.007) as independent predictors of seminal HIV detection. CONCLUSION: STIs and genital inflammation can partially override the suppressive effect of HAART on seminal HIV shedding in sexually active HIV-infected MSM. Low seminal HIV titers could potentially pose a transmission risk in MSM, who are highly susceptible to HIV infection.
OBJECTIVE: Although HAART can suppress genital shedding and sexual transmission of HIV, men who have sex with men (MSM) have experienced a resurgent HIV epidemic in the HAART era. Many HIV-infected MSM continue to engage in unsafe sex, and sexually transmitted infections (STIs) or other factors may promote genital HIV shedding and transmission in this population despite HAART. In this study, we determined the prevalence of seminal HIV shedding in HIV-infected MSM on stable HAART, and its relationship with a number of clinical, behavioral and biological variables. DESIGN:Sexually active HIV-infectedmen using HAART were recruited from an MSM health clinic to provide semen and blood samples. METHODS: HIV levels were assessed in paired semen and blood samples by PCR. Clinical and behavioral data were obtained from medical records and questionnaires. Herpes simplex virus 2 (HSV-2) serostatus, seminal HSV-2 DNA, and markers of genital inflammation were measured using standard laboratory methods. RESULTS: Overall, HIV-1 was detected in 18 of 101 (18%) blood and 30 of 101 (30%) semen samples. Of 83 men with undetectable HIV in blood plasma, 25% had HIV in semen with copy numbers ranging from 80 to 2560. Multivariate analysis identified STI/urethritis (P = 0.003), tumor necrosis factor α (P = 0.0003), and unprotected insertive anal sex with an HIV-infected partner (P = 0.007) as independent predictors of seminal HIV detection. CONCLUSION: STIs and genital inflammation can partially override the suppressive effect of HAART on seminal HIV shedding in sexually active HIV-infected MSM. Low seminal HIV titers could potentially pose a transmission risk in MSM, who are highly susceptible to HIV infection.
Authors: P L Vernazza; L Troiani; M J Flepp; R W Cone; J Schock; F Roth; K Boggian; M S Cohen; S A Fiscus; J J Eron Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer Journal: AIDS Date: 2010-01-16 Impact factor: 4.177
Authors: Seth C Kalichman; Lisa Eaton; Demetria Cain; Charsey Cherry; Andrea Fuhrel; Michelle Kaufman; Howard Pope Journal: Health Psychol Date: 2007-09 Impact factor: 4.267
Authors: Satish K Pillai; Benjamin Good; Sergei Kosakovsky Pond; Joseph K Wong; Matt C Strain; Douglas D Richman; Davey M Smith Journal: J Virol Date: 2005-02 Impact factor: 5.103
Authors: David M Butler; Davey M Smith; Edward R Cachay; George K Hightower; Charles Thomas Nugent; Douglas D Richman; Susan J Little Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Man E Charurat; Benjamin Emmanuel; Christopher Akolo; Babajide Keshinro; Rebecca G Nowak; Sara Kennedy; Ifeanyi Orazulike; Julie Ake; Ogbonnaya Njoku; Stefan Baral; William Blattner Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford Journal: J Virol Date: 2015-04-01 Impact factor: 5.103
Authors: Kristi E Gamarel; Sharon Nichols; Christopher W Kahler; Andrew O Westfall; Michelle A Lally; Craig M Wilson Journal: Sex Transm Infect Date: 2017-11-27 Impact factor: 3.519
Authors: Mackenzie L Cottrell; Kristine B Patterson; Heather M A Prince; Amanda Jones; Nicole White; Ruili Wang; Angela D M Kashuba Journal: Antivir Ther Date: 2015-06-03
Authors: Shayarana L Gooneratne; Jonathan Richard; Wen Shi Lee; Andrés Finzi; Stephen J Kent; Matthew S Parsons Journal: J Virol Date: 2014-10-15 Impact factor: 5.103
Authors: Benson Singa; Sara Nelson Glick; Naomi Bock; Judd Walson; Linda Chaba; James Odek; R Scott McClelland; Gaston Djomand; Hongjiang Gao; Grace John-Stewart Journal: Sex Transm Dis Date: 2013-02 Impact factor: 2.830